EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

De Novo Design of High-Affinity HER2-Targeting Protein Minibinders

Yize Zhao, Wenping Wei, Zijun Cheng, Min Yang, Yunjun Yan iD

Biomolecules · 12.11.2025 · 15 (11) · 1587

DOI: 10.3390/biom15111587 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, online erschienen am 12.11.2025. Verfasst von Yize Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Techn…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, China, Instrument Sharing Platform of the School of Life Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human Epidermal Growth Factor Receptor 2 (HER2) is a key therapeutic target in breast cancer. However, the application of existing anti-HER2 antibody drugs is limited by such issues as large molecular weight and poor stability. In this study, a series of small protein minibinders targeting HER2 domain IV were de novo designed using the RFdiffusion method. Candidate molecules were selected through a combination of ProteinMPNN and AlphaFold2 screening, and their binding capabilities were further evaluated using Escherichia coli surface display coupled with flow cytometry analysis. By integrating molecular dynamics simulations, confocal fluorescence imaging, and isothermal titration calorimetry (ITC) experiments, a highly efficient minibinder (0_703_6) with nanomolar affinity and a smaller molecular size was finally identified. Compared with the existing drug molecules, the identified minibinder exhibited approximately threefold higher affinity and a threefold reduction in molecular size. This study provides strong support for the development of novel, stable, and easily expressible HER2-targeted therapeutic molecules and also offers new insights into the rapid development of robust breast cancer drugs that may serve as ideal alternatives to monoclonal antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesHumansMolecular Dynamics SimulationProtein BindingBreast NeoplasmsFemaleEscherichia coliDrug Design

Stichwörter der Autor:innen

HER2Minibinderbreast cancerprotein de novo design

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430070, China.

ORCID-Profile: Yunjun Yan

Förderung

  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities, China
  • Instrument Sharing Platform of the School of Life Science and Technology
  • Huazhong University of Science and Technology

Zitieren

APA

Zhao, Y., Wei, W., Cheng, Z., Yang, M., & Yan, Y. (2025). De Novo Design of High-Affinity HER2-Targeting Protein Minibinders. Biomolecules, 15(11), 1587. https://doi.org/10.3390/biom15111587

Vancouver

Zhao Y, Wei W, Cheng Z, Yang M, Yan Y. De Novo Design of High-Affinity HER2-Targeting Protein Minibinders. Biomolecules. 2025;15(11):1587. doi:10.3390/biom15111587

BibTeX
@article{Zhao2025,
  author = {Zhao, Yize and Wei, Wenping and Cheng, Zijun and Yang, Min and Yan, Yunjun},
  title = {De Novo Design of High-Affinity HER2-Targeting Protein Minibinders},
  journal = {Biomolecules},
  year = {2025},
  volume = {15},
  number = {11},
  pages = {1587},
  doi = {10.3390/biom15111587}
}
Kostenlos starten →